Ulotaront Phase III Schizophrenia Setback For Sumitomo, Otsuka Alliance
'High Placebo Response'
Novel psychiatric drug has missed its Phase III efficacy endpoint in two Phase III trials, posing a potential blow to the Japanese firms' alliance plans in schizophrenia, although development in other CNS indications looks set to continue.
